Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 208 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015', provides an overview of the Idiopathic Pulmonary Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Idiopathic Pulmonary Fibrosis Overview 9
Therapeutics Development 10
Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview 10
Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis 11
Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies 12
Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 17
Idiopathic Pulmonary Fibrosis - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Idiopathic Pulmonary Fibrosis - Products under Development by Companies 21
Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 25
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 26
AdAlta Pty Ltd. 26
Aeolus Pharmaceuticals, Inc. 27
AnaptysBio, Inc. 28
Auspex Pharmaceuticals, Inc. 29
Biogen Idec Inc. 30
Bioneer Corporation 31
BiOrion Technologies B.V. 32
Boehringer Ingelheim GmbH 33
Bristol-Myers Squibb Company 34
Carolus Therapeutics, Inc. 35
Celgene Corporation 36
Chong Kun Dang Pharmaceutical Corp. 37
Compugen Ltd. 38
F. Hoffmann-La Roche Ltd. 39
FibroGen, Inc. 40
Five Prime Therapeutics, Inc. 41
GenKyoTex S.A. 42
Gilead Sciences, Inc. 43
GlaxoSmithKline plc 44
HanAll Biopharma Co., Ltd. 45
Histocell S.L. 46
iBio, Inc. 47
ImmuneWorks, LLC 48
Inventiva SAS 49
Kadmon Corporation, LLC 50
Kasiak Research Pvt. Ltd. 51
Kyorin Pharmaceutical Co., Ltd. 52
Lanthio Pharma B.V. 53
LTT Bio-Pharma Co., Ltd. 54
MedImmune, LLC 55
Moerae Matrix, Inc. 56
MSM Protein Technologies, Inc. 57
Pacific Therapeutics Ltd. 58
Pharmaxis Limited 59
Progenra, Inc. 60
Promedior, Inc. 61
ProMetic Life Sciences Inc. 62
Pulmatrix, Inc. 63
Sanofi 64
Therametrics holding AG 65
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 71
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
(pentoxifylline + acetylcysteine) - Drug Profile 77
AEOL-10150 - Drug Profile 78
AM-0010 - Drug Profile 81
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 82
Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile 83
BMS-986020 - Drug Profile 84
BOT-191 - Drug Profile 85
CC-539 - Drug Profile 86
CC-90001 - Drug Profile 87
CGEN-25009 - Drug Profile 88
CKD-942 - Drug Profile 89
CT-2009 - Drug Profile 90
FG-3019 - Drug Profile 91
FPA-008 - Drug Profile 93
GKT-137831 - Drug Profile 94
GKT-901 - Drug Profile 95
HC-016 - Drug Profile 96
HL-156FIB - Drug Profile 97
HR-017 - Drug Profile 98
IBIOCFB-03 - Drug Profile 99
ICG-001 - Drug Profile 100
interferon gamma-1b - Drug Profile 101
IVA-337 - Drug Profile 102
IW-001 - Drug Profile 103
KBP-7018 - Drug Profile 104
KD-025 - Drug Profile 105
lebrikizumab - Drug Profile 107
LP2 - Drug Profile 109
LT-0011 - Drug Profile 110
LTI-03 - Drug Profile 111
MMI-0100 - Drug Profile 112
Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile 113
MSM-735 - Drug Profile 114
NAS-911 - Drug Profile 115
nintedanib - Drug Profile 117
omipalisib - Drug Profile 121
PBF-1250 - Drug Profile 122
PBI-4050 - Drug Profile 123
pirfenidone - Drug Profile 124
PRM-151 - Drug Profile 125
PUR-1500 - Drug Profile 127
PXS-25 - Drug Profile 128
PXS-4820 - Drug Profile 129
PXS-64 - Drug Profile 130
Refacell-IPF - Drug Profile 131
RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 132
SAR-156597 - Drug Profile 133
SD-560 - Drug Profile 134
simtuzumab - Drug Profile 135
Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile 137
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile 138
Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile 139
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 140
SPL-334 - Drug Profile 141
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 142
Stem Cell Therapy for Lung Fibrosis - Drug Profile 143
STX-100 - Drug Profile 144
TD-139 - Drug Profile 145
tipelukast - Drug Profile 146
tralokinumab - Drug Profile 148
vismodegib - Drug Profile 150
ZL-2102 - Drug Profile 153
Idiopathic Pulmonary Fibrosis - Recent Pipeline Updates 154
Idiopathic Pulmonary Fibrosis - Dormant Projects 193
Idiopathic Pulmonary Fibrosis - Discontinued Products 194
Idiopathic Pulmonary Fibrosis - Product Development Milestones 195
Featured News & Press Releases 195
Appendix 203
Methodology 203
Coverage 203
Secondary Research 203
Primary Research 203
Expert Panel Validation 203
Contact Us 203
Disclaimer 204

List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2015 14
Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Development by Companies, H1 2015 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2015 29
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2015 30
Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 31
Idiopathic Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H1 2015 32
Idiopathic Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 33
Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H1 2015 34
Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H1 2015 35
Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2015 36
Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 37
Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 38
Idiopathic Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2015 39
Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2015 40
Idiopathic Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 41
Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2015 42
Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 43
Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2015 44
Idiopathic Pulmonary Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015 45
Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2015 46
Idiopathic Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2015 47
Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H1 2015 48
Idiopathic Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 49
Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2015 50
Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2015 51
Idiopathic Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H1 2015 52
Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva SAS, H1 2015 53
Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H1 2015 54
Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 55
Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 56
Idiopathic Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H1 2015 57
Idiopathic Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 58
Idiopathic Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H1 2015 59
Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2015 60
Idiopathic Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H1 2015 61
Idiopathic Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2015 62
Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2015 63
Idiopathic Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2015 64
Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2015 65
Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 66
Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2015 67
Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H1 2015 68
Idiopathic Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H1 2015 69
Assessment by Monotherapy Products, H1 2015 70
Assessment by Combination Products, H1 2015 71
Number of Products by Stage and Target, H1 2015 73
Number of Products by Stage and Mechanism of Action, H1 2015 76
Number of Products by Stage and Route of Administration, H1 2015 78
Number of Products by Stage and Molecule Type, H1 2015 80
Idiopathic Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 158
Idiopathic Pulmonary Fibrosis - Dormant Projects, H1 2015 197
Idiopathic Pulmonary Fibrosis - Discontinued Products, H1 2015 198